Clene’s technology addresses neurodegenerative diseases to improve cellular bioenergetic function with nanocatalysts. Current Phase 2 studies include treatment of multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease)–neurodegenerative diseases with high unmet medical need. This approach may have broad applications across therapeutic areas with impaired bioenergetics. Founded in 2013, Clene is based in Salt Lake City with R&D and manufacturing operations located in Maryland.
Clene Nanomedicine Raises $42.5 Million for Novel Treatment of ALS, MS, Parkinson’s Disease, Mark Tullis, August 28, 2020
Clene Announces Phase II Clinical Trial Results, November 5th, 2021
Clene Receives Award from US National Academy of Medicine, May 21st, 2021